 |
|
A Positron Emission Tomography Study of Quetiapine in Schizophrenia
A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy
Shitij Kapur, MD, PhD, FRCPC;
Robert Zipursky, MD, FRCPC;
Corey Jones, BSc;
C. S. Shammi, MD, FRCPC;
Gary Remington, MD, PhD, FRCPC;
Philip Seeman, MD, PhD
Arch Gen Psychiatry. 2000;57:553-559.
Background Quetiapine is a new atypical antipsychotic medication. As such, relatively little has been published regarding its in vivo effects at the dopamine type 2 (D2) and serotonin type 2a (5-HT2a) receptor systems. The following study was undertaken to explore these effects across the clinical dose range and relate this information to its clinical profile.
Methods Twelve patients with schizophrenia were randomly assigned to doses of 150 to 600 mg/d (n=3, at 150, 300, 450, and 600 mg/d) of quetiapine. After 3 weeks of treatment, D2 and 5-HT2a occupancy were measured using positron emission tomography (PET) imaging, 12 to 14 hours after the last dose. Clinical efficacy and adverse effect ratings were obtained at baseline, at the time of PET scanning, and at 12 weeks. Two additional patients were included to examine the effects of the drug 2 to 3 hours after last dose.
Results Quetiapine was an effective antipsychotic and improved the extrapyramidal symptoms and prolactin level elevation noted at baseline. It achieved these results with minimal (0%-27%) D2 occupancy 12 hours after the last dose. Study of the additional subjects revealed that quetiapine does give rise to transiently high (58%-64%) D2 occupancy 2 to 3 hours after a single dose that then decreases to minimal levels in 12 hours.
Conclusions Quetiapine shows a transiently high D2 occupancy, which decreases to very low levels by the end of the dosing interval. Quetiapine's low D2 occupancy can explain its freedom from extrapyramidal symptoms and prolactin level elevation. The data suggest that transient D2 occupancy may be sufficient for its antipsychotic effect. Future studies controlling for nonpharmacological effects as well as activities on other receptors will be necessary to confirm this suggestion.
From the Schizophrenia Program (Drs Kapur, Zipurksy, Jones, Shammi, and Remington) and PET Centre (Drs Kapur and Jones), the Clarke Division of the CAMH, Department of Psychiatry (Drs Kapur, Zipursky, Shammi, Remington, and Seeman), and the Department of Pharmacology, University of Toronto, Toronto, Ontario (Dr Seeman).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients
Catafau et al.
J Psychopharmacol 2008;22:882-894.
ABSTRACT
Brain and Plasma Pharmacokinetics of Aripiprazole in Patients With Schizophrenia: An [18F]Fallypride PET Study
Grunder et al.
Am. J. Psychiatry 2008;165:988-995.
ABSTRACT
| FULL TEXT
Prolactin and dopamine: What is the connection? A Review Article
Fitzgerald and Dinan
J Psychopharmacol 2008;22:12-19.
ABSTRACT
Possible intranasal quetiapine misuse
Morin
Am J Health Syst Pharm 2007;64:723-725.
ABSTRACT
| FULL TEXT
The role of emission tomography in pharmacokinetic and pharmacodynamic studies in clinical psychopharmacology.
Malizia
J Psychopharmacol 2006;20:100-107.
ABSTRACT
Equivalent Occupancy of Dopamine D1 and D2 Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics
Tauscher et al.
Am. J. Psychiatry 2004;161:1620-1625.
ABSTRACT
| FULL TEXT
Worsening Schizoaffective Disorder With Aripiprazole
REEVES and MACK
Am. J. Psychiatry 2004;161:1308-1308.
FULL TEXT
A PET Study of Dopamine D2 and Serotonin 5-HT2 Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone
Mamo et al.
Am. J. Psychiatry 2004;161:818-825.
ABSTRACT
| FULL TEXT
Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity
Bressan et al.
J Psychopharmacol 2004;18:124-127.
ABSTRACT
Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study
Katzenschlager et al.
J. Neurol. Neurosurg. Psychiatry 2004;75:295-297.
ABSTRACT
| FULL TEXT
Atypical Antipsychotics: Mechanism of Action
Seeman
Focus 2004;2:48-58.
ABSTRACT
| FULL TEXT
Mechanism of New Antipsychotic Medications: Occupancy Is Not Just Antagonism
Grunder et al.
Arch Gen Psychiatry 2003;60:974-977.
ABSTRACT
| FULL TEXT
Effectiveness of Switching to Quetiapine for Neuroleptic-Induced Amenorrhea
Takahashi et al.
J. Neuropsychiatry Clin. Neurosi. 2003;15:375-377.
ABSTRACT
| FULL TEXT
Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo Occupancy
Kapur et al.
J. Pharmacol. Exp. Ther. 2003;305:625-631.
ABSTRACT
| FULL TEXT
Resolution of Risperidone-Induced Hyperprolactinemia with Substitution of Quetiapine
Kunwar and Megna
The Annals of Pharmacotherapy 2003;37:206-208.
ABSTRACT
| FULL TEXT
Dopamine and antipsychotic drug action revisited
JONES and PILOWSKY
Br. J. Psychiatry 2002;181:271-275.
FULL TEXT
Quetiapine for Olanzapine-Induced Galactorrhea
KINGSBURY et al.
Am. J. Psychiatry 2002;159:1061-1061.
FULL TEXT
Elevation of Prolactin Levels by Atypical Antipsychotics
Turrone et al.
Am. J. Psychiatry 2002;159:133-135.
ABSTRACT
| FULL TEXT
Use of Quetiapine in Delirium: Case Reports
Torres et al.
Psychosomatics 2001;42:347-349.
FULL TEXT
Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis
Kapur and Seeman
Am. J. Psychiatry 2001;158:360-369.
ABSTRACT
| FULL TEXT
|
